Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $10.4 million.

  • Stoke Therapeutics' Total Non-Current Liabilities fell 8.02% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 8.02%. This contributed to the annual value of $2.5 million for FY2024, which is 93.47% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Total Non-Current Liabilities of $10.4 million as of Q3 2025, which was down 4.18% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Total Non-Current Liabilities registered a high of $53.1 million during Q1 2022, and its lowest value of $2.5 million during Q4 2024.
  • Its 3-year average for Total Non-Current Liabilities is $23.5 million, with a median of $20.6 million in 2024.
  • Data for Stoke Therapeutics' Total Non-Current Liabilities shows a maximum YoY tumbled of 93.47% (in 2024) over the last 5 years.
  • Stoke Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $39.8 million in 2022, then decreased by 4.69% to $38.0 million in 2023, then slumped by 93.47% to $2.5 million in 2024, then decreased by 8.02% to $10.4 million in 2025.
  • Its Total Non-Current Liabilities was $10.4 million in Q3 2025, compared to $10.9 million in Q2 2025 and $12.1 million in Q1 2025.